Experts in healthcare reimbursement and regulation,
providing customized consulting
and education services.

Training Programs

We bring the experts to you with a range of on-site education options and bootcamp style programs that teach how a firm grasp of the rules leads to operational excellence.

More information »

Audits & Assessments

Our team of specialized regulatory specialists can assist your organization in revving up your revenue cycle by auditing and assessing key processes for coding and billing.

More information »

Regulatory Monitoring

Our team is available for ongoing regulatory watchdog services that answer your questions and offer you the latest Medicare news, analysis and operational guidance.

More information »

Feb
17

February 9-16: CMS issues proposed, final decision memos, and more

Email This Post Print This Post

CMS clarifies enforcement of amended requirements for physician-owned hospitals and critical access hospital (CAH) disclosures to patients

On February 13, CMS issued a memo in which it clarifies its enforcement approach to certain changes in requirements, including revision to the physician-owned hospital disclosure requirements.

View the memo.

CMS issues decision memo for surgery for diabetes

On February 12, CMS issued a final decision memo in which it determined it would not make changes to National Coverage Determination (NCD) Manual section 100.8 (Intestinal Bypass Surgery) and section 100.11 (Gastric Balloon for Treatment of Obesity). Treatments for obesity alone remain non-covered.

View the decision memo.

View a related press release.

CMS issues proposed decision memo for screening computed tomography colonography (CTC) for colorectal cancer

On February 11, CMS proposed to maintain noncoverage of CTC for colorectal cancer screening.

View the proposed decision memo.

OIG issues comparison of second-quarter 2008 average sales prices (ASP) and average manufacturer prices (AMP) for Medicare Part B prescription drugs

On February 11, the OIG released a report comparing second-quarter ASPs to AMPs for Medicare Part B prescription drugs and its impact on Medicare fourth-quarter reimbursement.

View the OIG report.

Leave a Reply